Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors

Trial Profile

Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Everolimus (Primary)
  • Indications Nerve sheath neoplasms
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2016 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
    • 12 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jun 2017.
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top